Please use this identifier to cite or link to this item:
Title: Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells
Authors: Zhang, Y.
Ding, G.
Cheng, Y.
Sun, W.
Tao, J. 
Huang, H.
Keywords: Celecoxib
PC12 cells
Voltage-gated calcium channel (VGCC)
Whole-cell patch clamp
Issue Date: 2007
Citation: Zhang, Y., Ding, G., Cheng, Y., Sun, W., Tao, J., Huang, H. (2007). Effects of celecoxib on voltage-gated calcium channel currents in rat pheochromocytoma (PC12) cells. Pharmacological Research 56 (3) : 267-274. ScholarBank@NUS Repository.
Abstract: Cyclooxygenase-2 (COX-2) plays crucial roles in the development and invasion of tumors. Celecoxib, a selective COX-2 inhibitor, has been shown to be chemopreventive against cancer. However, to date, the mechanisms of these effects remain unclear. In this study, we investigate the effects of celecoxib on voltage-gated calcium channel (VGCC) currents in undifferentiated pheochromocytoma (PC12) cells using whole-cell patch clamp. Our results showed that celecoxib, instead of rofecoxib or NS-398, another selective COX-2 inhibitor, reversibly inhibited the current density of VGCC in a concentration-dependent manner, but had no apparent effects on the cells treated with nifedipine (1 μM), an L-type calcium channel blocker. Upon pre-incubation of PC12 cells with omega-conotoxia GVIA (1 μM), an N-type calcium channel blocker, omega-agatoxin IVA (1 μM), a P/Q-type calcium channel blocker, or SNX-482 (1 μM), a R-type calcium channel blocker, celecoxib (1 μM) inhibited the currents by 36%, 28%, and 25%, respectively. Celecoxib up-shifted the current-voltage (I-V), and hyperpolarizedly shifted the inactivation curve, but did not markedly affect the activation curve. Intracellular application of H89, a protein kinase A inhibitor, failed to affect the celecoxib's VGCC currents inhibition. Taken together, our present results suggested that celecoxib inhibited L-type calcium channels in PC12 cells via a COX-2 independent pathway, which might be responsible for its clinical effects including anti-tumor. © 2007.
Source Title: Pharmacological Research
ISSN: 10436618
DOI: 10.1016/j.phrs.2007.07.004
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Jun 6, 2020


checked on May 28, 2020

Page view(s)

checked on Jun 2, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.